
Biotherapic of Trypanosoma cruzi 17d increases apoptosis in experimentally infected mice
Author(s) -
PatrÃÂcia Flora Sandri,
Gislaine Janaína Sanchez Falkowski,
Luzmarina Hernandes,
Márcia Machado de Oliveira Dalálio,
Denise Lessa Aleixo,
Mà́nica LÃÂocia Gomes,
Anélio Dias Nascimento JÃÂonior,
Ricardo Alberto Moliterno,
Silvana Marques de AraÃÂojo
Publication year - 2021
Publication title -
international journal of high dilution research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.129
H-Index - 9
ISSN - 1982-6206
DOI - 10.51910/ijhdr.v10i36.467
Subject(s) - trypanosoma cruzi , benznidazole , apoptosis , in vivo , serial dilution , immune system , biology , chagas disease , pharmacology , immunology , chemistry , medicine , parasite hosting , biochemistry , pathology , microbiology and biotechnology , alternative medicine , world wide web , computer science
the mechanism of action of ultradiluted medicines has not yet been established[1,3]. Many basic research studies have focused on isopathic models using in vitro or in vivo designs [4,5]. Recent studies indicate that an ultradiluted (isopathic) antigen can transfer signals to the immune system and modulate its response when an organism is challenged against this same antigen [6]. Some studies on experimental infection of mice by T. cruzi identified apoptotic cells and showed that the increase of their number is associated with an increase also in the number of parasites in the blood of the infected animals, while blockage of apoptosis can be the target of therapeutic intervention [7,8].
Aim: to evaluate the development of apoptosis in mice treated with biotherapic of Trypanosoma cruzi in dilution 17d through in situ detection of fragmented DNA.
Method: in a blind randomized controlled trial, 36 male Swiss mice age 4 or 8 weeks were distributed in groups control - treated with 7% hydroalcoholic solution(CI-4=9 animals or CI-8=9 animals); and treated with biotherapic 17d (BIOT-4=9 animals or BIOT-8=9 animals). Infection was performed with 1,400 trypomastigotes T. cruzi-strain Y via intraperitoneal. Biotherapic 17d was prepared through the addition of 0.9ml of concentrated T. cruzi (10E+7 trypomastigotes/ml) to 9.1 ml of distilled water. The following dilutions were prepared in 86% hydroalcoholic solution until dilution 16d. Dilution 17d was prepared with 7% hydroalcoholic solution. It was performed microbiological control and biological risk in vivo. Treatment: 0.2 ml in 3 consecutive days, oral route, from the moment infection was verified. Animals were sacrificed on the 3rd day of treatment in a chamber saturated with ether. The liver and spleen were removed and fixated in 4% paraformaldehyde for 24 hours and then included in paraffin. Apoptosis was evaluated through DNA fragmentation – TUNEL technique (TdT dUTP-biotin Nick End Labeling (ApopTag® Peroxidade-Chemicon). For statistical analysis software Statistica 8.0 was used. This study was approved by the Ethics Committee for Animal Experimentation of UEM.
Results and Discussion: in the samples of liver of animals age 4 and 8 weeks either treated or not with biotherapic 17d it was found cells parasitized by amastigotes of T. cruzi with apoptotic bodies, or phagocytic cells with phagocytic vacuole with apoptotic marked material inside them. The number of cells in apoptosis in animals age 4 weeks was not significantly (p=0.03) larger in treated group BIOT-C4 than in control group CI-4 (Figure 1). In animals age 8 weeks, the number of cells in apoptosis was significantly (p